J Gynecol Oncol.
2021 Jan;32(1):e210. 10.3802/jgo.2021.32.e20.
The role of secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer: what do the trials tell us?
- Affiliations
-
- 1Department of Gynecologic Oncology, US Oncology Research, The Woodlands, TX, USA
- KMID: 2526290
- DOI: http://doi.org/10.3802/jgo.2021.32.e20
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Maximal cytoreductive effort in epithelial ovarian cancer surgery
- Efficacy and impact of PARPi monotherapy to subsequent platinum-based chemotherapy in BRCA1/2 mutant ovarian cancer patients with secondary platinum-sensitive relapse
- A single-arm phase II study of olaparib maintenance with pembrolizumab and bevacizumab in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer (OPEB-01)
- The role of topotecan as second-line chemotherapy in patients with recurrent epithelial ovarian cancer
- Secondary acute myeloid leukemia after platinum based chemotherapy for ovarian cancer
